@axon-neuroscience.eu
AXON Neuroscience SE is a biotech company dedicated to the development of disease modifying immunotherapy and early diagnostics for Alzheimer's disease.
📢
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
SVG
Icon
PNG
About
Description
Axon Neuroscience is an industry-leading clinical stage biotech company founded in 1999 with the mission to eradicate Alzheimer's disease. They focus on developing tau-based treatments that can halt the disease, relieve symptoms, and potentially prevent its onset. With over two decades of dedicated research, their expert team is at the forefront of treating and preventing Alzheimer's disease.
The company was founded by Professor Michal Novák, who made significant contributions to the understanding of Alzheimer's disease. Professor Novák discovered tau protein as the structural component of neurofibrillary tangles, a major hallmark of the disease, and proposed it as a valid target for therapy. Axon Neuroscience has since pioneered the clinical development of tau therapy and has the largest scientific team dedicated exclusively to tau immunotherapeutics.
Their first-in-man tau vaccine AADvac1 has shown positive results in clinical trials and has the potential to address a critical unmet medical need. Axon Neuroscience is dedicated to finding a tau-based treatment that will make a monumental impact on Alzheimer's disease victims and their families. In addition to their focus on Alzheimer's disease, Axon Neuroscience has also demonstrated their versatility by developing a vaccine and therapeutic antibodies against COVID-19, showcasing their research capabilities in a novel disease area.
The company has assembled an international team of leading experts in neuroscience and clinical drug development to support the design, conduct, and analysis of their clinical trials. Their leadership team includes individuals with extensive experience in the field, such as Chief Executive Officer Michal Fresser, Chief Science Officer Norbert Žilka, Chief Financial Officer Ladislav Satko, and Managing Director of Axon Neuroscience CRM and R&D Roman Sivák. Axon Neuroscience is committed to changing the narrative around Alzheimer's disease by providing effective treatment options and improving the lives of those affected by this devastating condition
Company Type
Privately Held
Company Size
51-200
Year Founded
1999
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere 👋
All services online